ReviewDiagnostics (Basel, Switzerland)2023
Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma.
Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- Clinicopathologic Outcomes After Resection of Suspected High-Grade Pancreatic Intraepithelial Neoplasia Without Invasive Carcinoma: A Multicenter Retrospective Study.Annals of surgical oncology · 2026Article
- Characterizing pancreatic cancer-associated fibroblast heterogeneity in vascular microphysiological systems.Angiogenesis · 2026Article
- Breaking Through the Barrier: Nanoparticle-Driven MRI Strategies for Diagnosis and Therapy of Pancreatic Cancer.ACS nanoscience Au · 2026Review
- Glycolytic heterogeneity drives metabolic-targeted therapy in pancreatic ductal adenocarcinoma.Signal transduction and targeted therapy · 2026Article
- Impact of concomitant use of renin-angiotensin system inhibitors on survival in patients with pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.Therapeutic advances in medical oncology · 2026Article
- Diagnosis and Surgical Management for Advanced Pancreatic Cancer Requiring Vascular Resection.Diagnostics (Basel, Switzerland) · 2025Review
- Gedunin Impacts Pancreatic Cancer Stem Cells Through the Sonic Hedgehog Signaling Pathway.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- Deciphering the Diagnostic Potential of Small Non-Coding RNAs for the Detection of Pancreatic Ductal Adenocarcinoma Through Liquid Biopsies.International journal of molecular sciences · 2025Article
- Article
- Tumor Organoids Grown in Mixed-Composition Hydrogels Recapitulate the Plasticity of Pancreatic Cancers.Gels (Basel, Switzerland) · 2025Article
- Mushroom Bioactive Molecules as Anticancerous Agents: An Overview.Food science & nutrition · 2025Review
- Acinar cell carcinoma of the pancreas: can CT and MR features predict survival?Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Immunohistochemical Evaluation of the Tumor Immune Microenvironment in Pancreatic Ductal Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2025Article
- Automatic detection of main pancreatic duct dilation and pancreatic parenchymal atrophy based on a shape feature in abdominal contrast-enhanced CT images.Journal of medical imaging (Bellingham, Wash.) · 2025Article
- PCDH1 facilitates migration, proliferation, and stemness of pancreatic cancer cells through PI3K-Akt signaling.Frontiers in oncology · 2025Article
- Review
- Review
- Screening for pancreatic cancer in high-risk individuals using MRI: optimization of scan techniques to detect small lesions.Familial cancer · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) can be treated with surgery, chemotherapy, and radiotherapy. Despite medical progress in each field in recent years, it is still insufficient for managing PDAC, and at present, the only curative treatment is surgery. A typical pancreatic cancer is relatively easy to diagnose with imaging. However, it is often not recommended for surgical treatment at the time of diagnosis due to metastatic spread beyond the pancreas. Even if it is operable, it often recurs during postoperative follow-up. In the case of PDAC with a diameter of 10 mm or less, the 5-year survival rate is as good as 80% or more, and the best index for curative treatment is tumor size. The early detection of pancreatic cancer with a diameter of less than 10 mm or carcinoma in situ is critical. Here, we provide an overview of the current status of diagnostic imaging features and genetic tests for the accurate diagnosis of early-stage PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.